Australia markets open in 32 minutes

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4200+0.0700 (+5.19%)
At close: 04:00PM EDT
1.5295 +0.11 (+7.71%)
After hours: 07:21PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3500
Open1.3800
Bid1.4100 x 100
Ask1.4400 x 100
Day's range1.3761 - 1.5200
52-week range0.8500 - 320.0000
Volume172,819
Avg. volume4,733,238
Market cap4.537M
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)-23.9000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est140.00
  • PR Newswire

    TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging NK (natural killer) cells in treating both solid tumors and other indications.

  • PR Newswire

    TCBP Increasing Treatment Capacity with Expanded Manufacturing Process

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000.

  • PR Newswire

    TCBP Adjourns General Meeting Until a Later Date

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has adjourned its General Meeting of the Company to a later date.